Weimai Qingtong Medical Technology (Wuxi) Co., Ltd. announced that it has received nears CNY 100 million in a round of funding on March 13, 2024. The transaction involved participation from new investor CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57.59 CNY | -2.77% | -4.76% | -15.52% |
Apr. 29 | Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 62 Yuan From 87 Yuan, Keeps at Hold | MT |
Apr. 26 | Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.52% | 3.44B | |
+1.36% | 264B | |
+19.84% | 20.44B | |
+12.30% | 12.29B | |
-12.64% | 9.5B | |
+16.55% | 7.6B | |
+11.43% | 6.16B | |
-2.43% | 4.24B | |
-13.62% | 3.92B | |
-6.81% | 3.67B |
- Stock Market
- Equities
- 300957 Stock
- News Yunnan Botanee Bio-Technology Group Co.LTD
- Weimai Qingtong Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd.